Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | IDH2 mutant |
| Therapy | HMPL-306 |
| Indication/Tumor Type | low grade glioma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH2 mutant | low grade glioma | predicted - sensitive | HMPL-306 | Phase I | Actionable | In a Phase I trial, HMPL-306 treatment was well tolerated in patients with low-grade glioma harboring mutations in IDH1 or IDH2 (n=17) and resulted in an objective response rate of 7.1%, disease control rate of 100%, and median progression-free survival of 20.5 months (J Clin Oncol 2025 43: 16_suppl, 2013; NCT04762602). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Phase 1 study of HMPL-306, an inhibitor of mutant IDH1/IDH2 (mIDH1/2), in western patients (pts) with advanced mIDH solid tumor, including glioma. | Full reference... |